TONIX Pharmaceuticals, Inc. CEO Dr. Seth Lederman Describes Potential Treatment for Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury
8/16/2012 9:46:25 AM
NEW YORK--(BUSINESS WIRE)--Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (“TONIX” or the “Company”) (OTCBB:TNXP) says that a good night’s sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE). Dr. Lederman made his remarks in an interview with the CEOLive Financial Network which is available at: http://ceolive.tv/tonix-pharmaceuticals/tnxp-videos/279-ceolive-investorinsight-series-featuring-tonix-pharmaceuticals-tnxp.
comments powered by